# Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001

> **NCT03625934** · PHASE2 · UNKNOWN · sponsor: **Viravaxx AG** · enrollment: 84 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** VVX001
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03625934
- **Lead sponsor:** Viravaxx AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-06
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2021-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625934, "Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03625934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*